Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Teva Pharmaceutical Industries Limited (IL:TEVA)
:TEVA
Earnings Data
Report Date
May 07, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
182.2Last Year’s EPS
178.2Same Quarter Last Year
Based on 0 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Jan 29, 2025
|% Change Since: -22.29%
|Next Earnings Date:May 07, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted strong growth in key product segments and positive financial metrics, supported by strategic advancements in the pipeline and improved credit ratings. However, challenges such as the impact of litigation payments, operational losses due to impairments, and FX headwinds were noted. The offsetting factors indicate a balanced performance with a cautiously optimistic outlook.Company Guidance
During the Teva Pharmaceutical Industries earnings call, the company provided substantial guidance for 2025, highlighting several key metrics. Teva anticipates revenue of $16.8 billion to $17.4 billion, indicating a growth rate of 2% to 5% compared to 2024. The company expects its non-GAAP adjusted EBITDA to be between $4.5 billion and $5 billion, reflecting consistency with the previous year's levels at the midpoint of the guidance range. Additionally, the non-GAAP earnings per share (EPS) is projected to be in the range of $2.35 to $2.65. Teva also plans to continue its strategic investments with an R&D expenditure exceeding 6% of revenue, focusing on advancing key pipeline assets. The company's free cash flow is expected to be between $1.6 billion and $1.9 billion, slightly lower than in 2024, due to adjustments in accounts receivable securitization and increased legal settlements. Despite these factors, Teva remains focused on maintaining a balanced approach to capital allocation to support both short- and long-term growth strategies.Strong Growth in Key Products
AUSTEDO achieved a 34% increase, UZEDY surpassed its target with $117 million, and AJOVY grew by 18% reaching $0.5 billion.
Sustained Revenue Growth
Teva reported $16.5 billion in revenue, a 9% increase, with adjusted EBITDA also rising by 9% to $4.8 billion.
Positive Financial Metrics
Non-GAAP EPS increased by 10% to $2.49, and free cash flow grew by 10% to $2.1 billion.
Strategic Progress in Generics and Biosimilars
Generics business grew by 11%, and the company plans to launch seven biosimilar assets in the US and four in Europe by 2027.
Pipeline Advancements
Significant progress in late-stage products such as olanzapine, ICS/SABA DARI, and duvakitug, with promising future indications.
Improved Credit Ratings
All three major credit rating agencies upgraded Teva's ratings and outlook, recognizing improved growth prospects.
---
IL:TEVA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
IL:TEVA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Jan 29, 2025 | 7960.00 | 6785.00 | -14.76% |
| Nov 06, 2024 | 6952.00 | 6650.00 | -4.34% |
| Jul 31, 2024 | 6188.00 | 6450.00 | +4.23% |
| May 08, 2024 | 5148.00 | 5815.00 | +12.96% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Teva Pharmaceutical Industries Limited (IL:TEVA) report earnings?
Teva Pharmaceutical Industries Limited (IL:TEVA) is schdueled to report earning on May 07, 2025, TBA Not Confirmed.
What is Teva Pharmaceutical Industries Limited (IL:TEVA) earnings time?
Teva Pharmaceutical Industries Limited (IL:TEVA) earnings time is at May 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Teva Pharmaceutical Industries Limited stock?
The P/E ratio of Teva is N/A.
What is IL:TEVA EPS forecast?
IL:TEVA EPS forecast for the fiscal quarter 2025 (Q1) is 182.2.
---